logo
Plus   Neg
Share
Email

Threshold Pharma Gives New Data On TH-302 And Avastin In Recurrent Glioblastoma

Biotechnology company Threshold Pharmaceuticals, Inc. (THLD) Friday announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 in combination with Avastin (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure.

The company noted that no dose-limiting toxicity has been reported to date at doses of TH-302 up to 670 mg/m2 plus bevacizumab at 10 mg/m2 every two weeks. Preliminary data in 14 patients showed TH-302 in combination with bevacizumab was associated with a median time to progression of 2.8 months. One patient achieved a complete response and two patients achieved partial responses.

The company will present the data today at the 4th Quadrennial World Federation of Neuro-Oncology meeting held in conjunction with the 18th annual 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology, San Francisco, CA.

Chemotherapy with radiotherapy is standard care for newly diagnosed glioblastoma. Bevacizumab is approved in the U.S. for progressive disease following prior therapy.

Andrew Brenner, Principal Investigator of the study, said, "These preliminary data signal that TH-302 in combination with bevacizumab may have activity in patients with glioblastoma following single-agent bevacizumab failure. We are looking forward to further evaluation of TH-302 as this study continues to enroll patients."

The ongoing phase 1/2 trial is a single-center, dose-escalation trial in patients with recurrent glioblastoma whose disease has progressed following initial combined modality treatment with radiotherapy and temozolomide and subsequent treatment with bevacizumab.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A New York regulator has launched an investigation into the credit card practices of Goldman Sachs Group Inc. for alleged gender discrimination in determining limits for Apple's new credit card, which is administered by Goldman Sachs. The Apple Card, Apple's first credit card, was introduced by the tech giant in March this year in partnership with Goldman Sachs and Mastercard. The U.S. Food and Drug Administration approved the first therapy for patients with a rare inherited blood disorder called beta thalassemia. Celegene's Reblozyl is also the first and only FDA-approved erythroid maturation agent, a new class of therapy for such patients. The regulator approved Reblozyl for treating anemia in adult patients with beta thalassemia who require regular RBC transfusions. McDonald's is adding renewable energy to the grid, as part of its efforts to address climate change. The fast-food giant said it signed two long-term, large-scale virtual power purchase agreements or VPPAs to buy renewable energy generated by wind and solar power. Under the agreements, McDonald's will buy a combined 380MW in renewable energy.
Follow RTT
>